First-generation Receptor Tyrosine Kinase (RTK)-directed targeted therapies such as highly target-specific anti-IGF-1R antibodies have shown encouraging clinical effects, albeit in small subsets of patients, and mainly in ES (3–7). Here, NTRK1 is linked to Ewing sarcoma.